PeptideStack
5.2kquestions
20kanswers
220users

How do PCAB accreditation and USP <797> beyond-use dating actually constrain a compounded vial?

Asked 19 Nov 2025Modified 6 months agoViewed 12k times
16

I was sent a compounded multi-dose vial with a beyond-use date 90 days out, refrigerated, and a note saying the pharmacy is "PCAB accredited and USP 797 compliant". Both phrases were presented as reassurance and I have no idea whether they are load-bearing or wallpaper.

What I would like to understand:

  • What does PCAB accreditation actually audit, and who grants it?
  • Is a beyond-use date the same thing as an expiry date? The pharmacy used both words in one email.
  • Is 90 days refrigerated a normal BUD for a preparation made from a powder, or does that number imply something specific about how the vial was made and tested?

The reason I care is that I have a second vial from a different pharmacy with a 28-day BUD for what appears to be the same preparation, and one of those two numbers is doing something the other is not.

compounding
compounding

Compounded preparations: what a 503A and a 503B facility may legally prepare and when, base versus salt forms, beyond-use dating under USP…

61 questions
pharmacy-503a
pharmacy-503a

Section 503A traditional compounding pharmacies specifically: patient-specific prescriptions, accreditation such as PCAB and ACHC, USP 797…

17 questions
sterility
sterility

Sterility as a test result rather than an adjective. Covers what a sterility test actually measures, why "sterile filtered" on a document is close…

122 questions
shelf-life
shelf-life

How long a preparation remains within specification: labelled expiry for a sealed lyophilised vial, beyond-use dating after reconstitution, and…

301 questions
shareeditfollowflag
MT
askedmarcus_thorbjorn16k2819 Nov 2025
7Ask which USP 797 category the preparation was assigned. That single word predicts the BUD almost completely. – Dr_Idris_Coulibaly 2 months ago
6A 90-day and a 28-day BUD on the same preparation is exactly the question worth asking the pharmacies. – Dr_Ilse_Vandenberg 1 days ago
add a comment

3 Answers

Accepted answer first, then by votes
39

Accepted answer

They are not the same word, and the gap between your two vials is almost certainly a category difference plus a sterility test, not a disagreement about chemistry.

BUD is not expiry

An expiration date belongs to a manufactured product and is supported by stability studies on that formulation in that container closure, run to a protocol, with assay data at each timepoint. A beyond-use date is assigned to a compounded preparation and, under the sterile-compounding chapter, is primarily a microbiological limit — a statement about how long the preparation can be relied upon to remain sterile given how it was made, not a statement that the drug is still at label strength. Those are different guarantees. A vial within its BUD is presumed sterile; it is not thereby proven potent.

Where the numbers come from

The revised sterile-compounding chapter sorts preparations into categories, and the category plus a small number of facts sets the maximum BUD. Simplified, for aseptically processed preparations:

Category and how madeRoom tempRefrigeratedFrozen
Category 1 (compounded in an unclassified segregated area)12 hours24 hours
Category 2, from nonsterile components, no sterility test1 day4 days45 days
Category 2, from sterile components only, no sterility test4 days10 days45 days
Category 2, from nonsterile components, sterility test passed30 days45 days60 days
Category 2, from sterile components only, sterility test passed45 days60 days90 days
Category 3 (extra controls, testing and stability data)up to 60 daysup to 90 daysup to 180 days

Read your two vials against that. A preparation made by dissolving a nonsterile powder and filtering is "from nonsterile components". Without a sterility test that caps at 4 days refrigerated, which nobody is shipping. With a passing sterility test it reaches 45 days refrigerated. To get to 90 days refrigerated you are in Category 3 territory, which is a substantially heavier regime: additional environmental and personnel controls, sterility and bacterial endotoxin testing, and — the part that matters here — documented stability data supporting the assigned date, not just a microbiological argument.

So the honest reading of your two vials is that the 28-day pharmacy is sitting comfortably inside a Category 2 sterility-tested envelope, and the 90-day pharmacy is either operating a Category 3 programme, or has assigned a date its process does not support. Both are possible. The way to tell them apart is to ask, in one sentence: "which category was this preparation assigned, was a sterility test performed and released on this lot, and what stability data supports the assigned BUD?" A Category 3 operation answers with documents. The other kind answers with adjectives.

PCAB

PCAB is the Pharmacy Compounding Accreditation Board, now operating as a compounding-specific accreditation service of the Accreditation Commission for Health Care. It is voluntary, third-party, and it audits the quality system: written master formulation and compounding records, personnel training and competency including gloved-fingertip and media-fill testing, environmental monitoring, cleaning and garbing procedures, equipment calibration, ingredient sourcing and COA review, and BUD assignment rationale. Surveyors visit the site. That is a real audit, and an accredited pharmacy has demonstrably been looked at by someone who understands the chapters.

What it is not: it is not FDA approval of any product, it does not test your specific vial, and it does not make the preparation a licensed drug. Accreditation tells you the process was audited on a date. Release data tells you about the thing in your hand. You want both, and only one of them is a marketing phrase.

Verify the claim rather than accept it — accreditation status is checkable with the accreditor, and "USP 797 compliant" is self-asserted by definition, since nobody issues 797 certificates.

edited 25 Jan 2026 by tyndall_haze — added the placebo-arm figures

shareimprove this answerflag
TH
answered · acceptedtyndall_haze48k481 Jan 2026
6The one-sentence question at the end is the whole answer. Category, sterility release, stability basis. – vial_five 6 months ago
5Worth adding that BUD restarts nothing on first puncture. In-use limits are a separate and usually shorter clock. – tobias_maartens 5 months ago
add a comment
Sponsored

Janoshik Analytical - Independent Third-Party Testing

HPLC purity, identity confirmation and quantified content on the vial you actually hold. Reports arrive with the chromatogram attached, not just a number.

Submit a sample
Sponsored — paired listing

GL Biochem (Shanghai) Ltd. - Direct Synthesis

Founded 1998. ISO 9001 and cGMP certified, 1,500+ staff and 200+ patents. The synthesis house behind a great many of the vials that get sent out for testing - batch-specific documentation with every order.

Visit GL Biochem
22

Following the comment above, because it is the part that trips people up after they have understood BUDs: the in-use period is a second, shorter clock and it starts at first puncture.

The BUD on the label is the unpunctured storage limit. Once the closure is entered, you have a container that has been broached, potentially repeatedly, and the relevant limit is whatever in-use dating the pharmacy specifies — often 28 days for a preservative-containing multi-dose preparation, and considerably shorter for one with no antimicrobial preservative. A preparation with no preservative in a multi-dose presentation is a design contradiction worth noticing: nothing in the vial is inhibiting growth between punctures.

So ask two dates, not one: unpunctured BUD, and in-use limit after first entry, with the storage condition for each. Then check that they are consistent with each other. A vial with a 90-day BUD and a 28-day in-use limit is coherent. A vial with a 90-day BUD, no stated in-use limit, and no preservative on the ingredient list is telling you the pharmacy has not thought about the second clock at all.

Second point: the BUD says nothing about potency, and for peptides potency is the thing that quietly degrades. Deamidation, oxidation of susceptible residues, and aggregation all proceed in solution at 4 degrees Celsius, slowly but not at zero rate, and none of them produce a visible change until aggregation gets far enough to scatter light. If your assigned BUD came from the microbiological table rather than from stability data on that formulation, then a vial at day 85 is within its date and has an unknown assay. That is not a scandal, it is just what a BUD is, and it is a good reason to prefer shorter dating and smaller vials over the longest number you can find.

shareimprove this answerflag
TW
answeredtare_weight47k3821 Dec 2025
11

On why the same nominal preparation varies in measured potency between compounders, which is the practical reason all of the above matters.

Sources of variance, roughly in order of magnitude:

  1. Net peptide correction. If one pharmacy corrects the weighing for net peptide content on the incoming lot and another weighs gross powder, you get a systematic difference of ten percent or more before anything else happens. This is the biggest single factor and it is invisible.
  2. Small-scale weighing error. Weighing tens of milligrams of a hygroscopic, statically charged fluffy solid is genuinely difficult. Balance resolution, static, and moisture pickup during handling all bite at that scale.
  3. Adsorption losses. Peptides adsorb to filter membranes, tubing and glass. A 0.22 micron sterilising filtration can retain a measurable fraction of a dilute peptide solution unless the membrane chemistry is chosen for low binding and the line is appropriately primed. Two pharmacies with different filters lose different amounts.
  4. Overfill and fill-volume variation. Filling to a target volume with a hand-operated pump has a spread. Deliberate overfill to guarantee extractable dose adds a further systematic offset in the other direction.
  5. Incoming API variation. Different bulk lots, sometimes different manufacturers, with genuinely different assay values.
  6. Assay method differences. When potency is checked at all, area-percent purity and a content assay against a traceable reference standard give different numbers, and reporting one as though it were the other creates apparent disagreement that is really a units problem.

None of these are exotic failures; they are the ordinary variance of small-batch aseptic work without CGMP release testing. It is why a content assay on the finished preparation — not on the incoming powder — is the only document that actually tells you what is in the vial you were sent.

shareimprove this answerflag
DS
answeredDr_Ravi_Selvarajah42k13810 Dec 2025
Filter adsorption is badly underrated. We measured a meaningful loss on a dilute peptide until the membrane was switched. – coldbox9 33 days ago
add a comment

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.